Cypress Buys Lupus Test
Luke Timmerman2/24/09
Cypress Bioscience (NASDAQ: CYPB), the San Diego-based developer of a drug for fibromyalgia, said today it has acquired technology from Cellatope to diagnose and monitor hard-to-detect autoimmune diseases like lupus. Cypress and its partner, New York-based Forest Laboratories, won FDA approval last month for milnacipran (Savella) as a treatment for a chronic muscle pain condition called fibromyalgia. Cypress plans to market that drug to rheumatology specialists, along with a range of other products to those doctors.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
